Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | SYK | P43405 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
| ▸ | AIMP2 | Q13155 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3458627 | 0.94 | EPHX2 (0.64) | EPHX2EGFRKDM4EALDH1A1HTT | |
| SCHEMBL14578174 | 0.90 | EPHX2 (0.61) | SRCSYKEPHX2KDM4ETP53 | |
| SCHEMBL4880015 | 0.89 | AIMP2 (0.57) | SRCAIMP2KDM4EALDH1A1HTT | |
| SCHEMBL3459161 | 0.88 | SRC (0.57) | SRCSYKEPHX2EGFRBTK | |
| SCHEMBL4209736 | 0.87 | EPHX2 (0.54) | SRCSYKEPHX2EGFRBTK | |
| SCHEMBL4878754 | 0.85 | AIMP2 (0.54) | SRCSYKEPHX2EGFRBTK | |
| SCHEMBL7464926 | 0.84 | AIMP2 (0.58) | SRCSYKEPHX2EGFRBTK | |
| SCHEMBL14621966 | 0.82 | EPHX2 (0.59) | EPHX2KDM4ETP53TSHRALDH1A1 | |
| SCHEMBL13924596 | 0.82 | SYK (0.62) | SRCSYKEGFRBTKAIMP2 | |
| SCHEMBL12837450 | 0.80 | ALDH1A1 (0.60) | EPHX2KDM4ETP53TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| EP-2154967-A1 | PYRIMIDINE DERIVATIVES | Hutchison Medipharma Enterprises Limited (BS) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008128231-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | SRC 4249/4885SYK 2248/4885EPHX2 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.